As Paul Aisen, MD, was making headlines last month for reporting positive data for solanezumab at the Alzheimer's Association International Conference, he was simultaneously embroiled in a legal battle for taking a new job and trying to bring one of the biggest projects in Alzheimer's research with him.
Trending:
CA schools wage legal battle over Alzheimer's data